Perhaps not, suggest these findings from a study of combination therapy's effect on carotid-artery intima-media thickness Ezetimibe, a novel cholesterol-absorption inhibitor marketed in the U.S. since ...

Combining Merck & Co and Schering Plough’s ezetimibe with statin drugs provides significant benefits in patients with elevated cholesterol, according to studies presented at the World Congress of ...

When every clinical outcome was counted in the IMPROVE-IT trial, including the first cardiovascular event and those that occurred thereafter, adding ezetimibe on top of simvastatin therapy provided ...

LONDON — A new analysis of the IMPROVE-IT trial indicates that the nonstatin, cholesterol-lowering drug ezetimibe (Zetia, Merck) is of specific benefit in patients with acute coronary syndrome who ...

Ezetimibe added to statin therapy showed a benefit in patients with diabetes who were admitted to the hospital with acute coronary syndrome (ACS), according to a study presented the European Society ...

Please provide your email address to receive an email when new articles are posted on . It is well known that HMG-CoA reductase inhibitors reduce LDL, a surrogate marker in atherosclerotic disease, as ...

Please provide your email address to receive an email when new articles are posted on . When the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, more commonly known as IMPROVE-IT ...

A US Food and Drug Administration (FDA) advisory committee voted yesterday against approving a claim that adding ezetimibe, marketed as Zetia by Merck/Schering-Plough, to statin therapy reduces the ...